Abstract
Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of less than 20 days was associated with prolonged overall survival (p less than 0.015). In those patients who eventually were found to be disease-free at surgical surveillance procedures, normalization of serum CA 125 levels to less than 35 U/ml within 65 days of primary operation also suggested an improved survival (p less than 0.059).
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma, Mucinous / diagnosis
-
Adenocarcinoma, Mucinous / drug therapy
-
Adenocarcinoma, Mucinous / surgery
-
Adult
-
Aged
-
Aged, 80 and over
-
Antigens, Tumor-Associated, Carbohydrate / analysis
-
Antigens, Tumor-Associated, Carbohydrate / metabolism*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma / diagnosis*
-
Carcinoma / drug therapy
-
Carcinoma / surgery
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Female
-
Follow-Up Studies
-
Half-Life
-
Humans
-
Middle Aged
-
Ovarian Neoplasms / diagnosis*
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / surgery
-
Prognosis
-
Time Factors
Substances
-
Antigens, Tumor-Associated, Carbohydrate
-
Cyclophosphamide
-
Cisplatin